Conference Coverage

BRAF-Plus-MEK Inhibition Slows Melanoma


 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

The abstract can be viewed at www.abstract.asco.org, and will be formally presented at ASCO at 3:30 p.m. June 4.

The trial was funded by GlaxoSmithKline. Dr. Weber reports consulting for and receiving honoraria and research funding from GSK. His coauthors report similar relationships, as well as employment/leadership positions and stock ownership with GSK.

* Updated: This paragraph was added on May 18, 2012.

Pages

Recommended Reading

Melanoma on Scalp Signals Worse Prognosis Than Other Sites
MDedge Hematology and Oncology
Limb Perfusion for In-Transit Melanoma Reduces Distant Recurrences
MDedge Hematology and Oncology
Cancer Diagnosis Appears to Raise Suicide, Cardiovascular Risks
MDedge Hematology and Oncology
Cyclops Lambs Played Important Role in Vismodegib's Approval
MDedge Hematology and Oncology
Gains in Melanoma Survival Attributed to Patient Awareness
MDedge Hematology and Oncology
Total Body Exam Reduces Melanoma Mortality
MDedge Hematology and Oncology
Early Detection of Melanoma: Harnessing Untapped Resources
MDedge Hematology and Oncology
New Dermoscopic Insights Gleaned for Mucosal Lesions
MDedge Hematology and Oncology
Women 30% More Likely to Survive Melanoma Than Men
MDedge Hematology and Oncology
CDC: Indoor Tanning, Sunburns Still Common in Young Adults
MDedge Hematology and Oncology